AOP-Wiki

API

All KERs

Showing 1626 to 1650 of 3102 KERs

ID	Upstream Event	Downstream Event	Creation Date	Last Updated	AOPs

2968	1339: Increase, intracellular calcium	1262: Apoptosis	Jul 18, 2023	Apr 11, 2024	1 AOP 500: Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis
3140	1339: Increase, intracellular calcium	177: Increase, Mitochondrial dysfunction	Mar 6, 2024	Apr 11, 2024	1 AOP 500: Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis
146	134: Increase, Kupffer cell activation	209: Peptide Oxidation	Nov 29, 2016	Dec 3, 2016	None
147	134: Increase, Kupffer cell activation	276: Up Regulation, TGFbeta1 expression	Nov 29, 2016	Nov 29, 2016	None
3726	134: Increase, Kupffer cell activation	1489: Increase, Steatohepatitis	Feb 10, 2026	Feb 10, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
1477	1378: Increase, leukocyte adherence	1379: Activate, leukocyte	Apr 17, 2017	Apr 17, 2017	1 AOP 217: Gastric ulcer formation
3591	2347: Increase, Lipid degradation	459: Increase, Liver steatosis	Aug 16, 2025	Aug 16, 2025	1 AOP 591: DBDPE-induced DNA damage increase in liver leading to Non-alcoholic fatty liver disease via liver steatosis and inhibition of regeneration
3545	2332: Increase, Lipid droplet	2333: Increase, Fat mass	Jul 25, 2025	Jul 25, 2025	1 AOP 580: Mineralocorticoid Receptor Activation Leading to Increased Body Mass Index
3551	2332: Increase, Lipid droplet	2337: Increase, PLIN2	Jul 25, 2025	Jul 25, 2025	1 AOP 580: Mineralocorticoid Receptor Activation Leading to Increased Body Mass Index
1599	1445: Increase, LPO	1446: Decrease, Coupling of OXPHOS	Jun 29, 2017	Jun 29, 2017	3 AOPs 331: Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death 332: Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell growth 333: Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation
2097	1445: Increase, LPO	1772: Decrease, TAG	Apr 30, 2020	Apr 30, 2020	1 AOP 329: Excessive reactive oxygen species production leading to mortality (3)
2210	1445: Increase, LPO	1365: Increase, Apoptosis	Nov 25, 2020	Nov 25, 2020	None
2222	1445: Increase, LPO	1825: Increase, Cell death	Dec 4, 2020	Dec 4, 2020	None
2464	1445: Increase, LPO	1607: Increase, Necrosis	Aug 11, 2021	Aug 11, 2021	1 AOP 413: Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure
2879	1445: Increase, LPO	406: decreased, Fertility	Apr 5, 2023	Sep 14, 2023	1 AOP 492: Glutathione conjugation leading to reproductive dysfunction via oxidative stress
3117	1445: Increase, LPO	2206: Increased, histomorphological alteration of testis	Jan 24, 2024	Apr 11, 2024	1 AOP 521: Essential element imbalance leads to reproductive failure via oxidative stress
3360	1445: Increase, LPO	55: Cell injury/death	Oct 8, 2024	Oct 8, 2024	None
3364	1445: Increase, LPO	1505: Cell cycle, disrupted	Oct 8, 2024	Oct 8, 2024	None
3569	1445: Increase, LPO	1994: Ferroptosis	Aug 13, 2025	Aug 13, 2025	None
3713	1445: Increase, LPO	902: Inflammation, Liver	Jan 19, 2026	Jan 19, 2026	1 AOP 615: Suppression of Keap1 cysteine oxidation leading to liver inflammation
169	161: Increase, Liver and splenic hemosiderosis	173: N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number	Nov 29, 2016	Dec 3, 2016	1 AOP 31: Oxidation of iron in hemoglobin leading to hematotoxicity
3729	344: Increase, Liver fibrosis	2406: Increase, Regenerative nodule formation	Feb 10, 2026	Feb 10, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
1695	459: Increase, Liver steatosis	1115: Increase, ROS	Nov 14, 2017	Nov 14, 2017	1 AOP 213: Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH)
3218	459: Increase, Liver steatosis	55: Cell injury/death	May 14, 2024	Jan 30, 2025	1 AOP 494: AhR activation leading to liver fibrosis
3592	459: Increase, Liver steatosis	2019: Non-alcoholic fatty liver disease	Aug 16, 2025	Aug 16, 2025	1 AOP 591: DBDPE-induced DNA damage increase in liver leading to Non-alcoholic fatty liver disease via liver steatosis and inhibition of regeneration

Key Event Relationships (KERs)

All KERs